Bristol Myers Squibb (BMY) Cash from Operations Growth (3y) (2012 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (BMY) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 39.10% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 21.60% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 56.97% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 52.90% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 18.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.60% |
| Mar 31, 2026 | -28.10% |
| Dec 31, 2025 | -15.79% |
| Sep 30, 2025 | 19.62% |
| Jun 30, 2025 | 20.10% |
| Mar 31, 2025 | -19.97% |
| Dec 31, 2024 | 3.04% |
| Sep 30, 2024 | 2.02% |
| Jun 30, 2024 | -8.74% |
| Mar 31, 2024 | -9.50% |
| Dec 31, 2023 | 8.22% |
| Sep 30, 2023 | 27.97% |
| Jun 30, 2023 | -25.11% |
| Mar 31, 2023 | -8.97% |
| Dec 31, 2022 | 14.87% |
| Sep 30, 2022 | 12.99% |
| Jun 30, 2022 | 2.77% |
| Mar 31, 2022 | 39.97% |
| Dec 31, 2021 | 4.50% |
| Sep 30, 2021 | 60.28% |